Combination of methotrexate with oral disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review.
Tyng-Shiuan HsiehTsen Fang TsaiPublished in: Immunotherapy (2023)
Background: Oral conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), especially methotrexate, are the cornerstone of treating psoriatic arthritis (PsA). The use of csDMARDs with biologics has increased their efficacy in psoriasis. However, the combination of two oral DMARDs in patients with PsA has not been adequately reviewed. In this study, we explore the combinational use of methotrexate with DMARDs in PsA patients. Materials & methods: A review was conducted using Medline (PubMed), Embase, Web of Science and the Cochrane Library, covering articles up to February 2023. Results & conclusion: Nine studies comprising 1993 participants were included. The evidence supporting combination therapy remains limited. Combinational therapy could be considered in patients with inadequate response to monotherapy or no access to biologics.
Keyphrases
- combination therapy
- prostate cancer
- rheumatoid arthritis patients
- high dose
- rheumatoid arthritis
- end stage renal disease
- radical prostatectomy
- ejection fraction
- newly diagnosed
- chronic kidney disease
- public health
- patient reported outcomes
- peritoneal dialysis
- randomized controlled trial
- low dose
- stem cells
- open label
- mesenchymal stem cells
- study protocol
- atopic dermatitis
- double blind
- smoking cessation